|
Veeda Oncology Acquires Biologie et Industrie, Based in Paris
Veeda Oncology, the subsidiary of one of the leading Global CRO's in India, Veeda Clinical Research, has completed the acquisition of Biologie et Industrie (B & I), an Oncology CRO founded in 1984, based in Paris, France. The acquisition of B & I, with over 20 years of oncology CRO experience, significantly compliments Veeda Oncology's capability within mainland Europe.
 Print View
May 24, 2008 (FPRC) -- Veeda Oncology, the subsidiary of one of the leading Global CRO's in India, Veeda Clinical Research, has completed the acquisition of Biologie et Industrie (B & I), an Oncology CRO founded in 1984, based in Paris, France. The acquisition of B & I, with over 20 years of oncology CRO experience, significantly compliments Veeda Oncology's capability within mainland Europe.
Announcing the acquisition, Mr. Binoy Gardi, Co-Managing Director of the Veeda Group, said "the acquisition of B & I is one significant pillar that we are adding to our global oncology presence within the oncology CRO marketplace". Mr. Gardi added that "the clients of B & I will now be able to enjoy the strong global oncology patient accrual ability that currently exists within Veeda Oncology as well as the other full service capabilities that Veeda Oncology provides to their clients".
Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure. Veeda Oncology feels that the acquisition of B & I truly strengthens Veeda Oncology’s capabilities
Dr. Rémy Brossel, MD and Dr. (Mrs.) Sylvie Brossel, MD, will both remain with the company to lead the operations within Europe. Dr. Rémy Brossel is tremendously excited with the blending of B & I with Veeda Oncology since it will allow B & I to " participate in the global environment for oncology clinical trials for our clients and to add greatly to the capacity that we can provide our clients. Now, we can effectively provide access to patients in the US, Eastern Europe, India as well as central Europe."
Mr. Matt Bowman, President and CEO of Veeda Oncology, said "the addition of both Drs. Rémy and Sylvie Brossel and their team from B & I will have a great impact on our European presence. Combining this with our organization in Gorlitz, Germany allows for significant growth potential within the European market. In addition, all of our global clients will benefit from the 20 years of oncology expertise that B & I will bring to Veeda."
Veeda Clinical Research
http://www.veedacr.com
Send an email to veedacr of http://www.Veedacr.com
+91 79 3001 3000
Keywords:
Clinical Research, Clinical Trials India
|
